JP2019515926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515926A5 JP2019515926A5 JP2018556339A JP2018556339A JP2019515926A5 JP 2019515926 A5 JP2019515926 A5 JP 2019515926A5 JP 2018556339 A JP2018556339 A JP 2018556339A JP 2018556339 A JP2018556339 A JP 2018556339A JP 2019515926 A5 JP2019515926 A5 JP 2019515926A5
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- disease
- hdl
- atherosclerosis
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 15
- 210000001519 tissue Anatomy 0.000 claims 10
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 4
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 4
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 208000026758 coronary atherosclerosis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- SARYOFMRLSHZFE-ZHACJKMWSA-N (e)-3-(2,5-dimethylanilino)-1-phenylprop-2-en-1-one Chemical compound CC1=CC=C(C)C(N\C=C\C(=O)C=2C=CC=CC=2)=C1 SARYOFMRLSHZFE-ZHACJKMWSA-N 0.000 claims 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023060872A JP2023085437A (ja) | 2016-04-29 | 2023-04-04 | 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662329676P | 2016-04-29 | 2016-04-29 | |
| US62/329,676 | 2016-04-29 | ||
| PCT/US2017/030444 WO2017190145A1 (en) | 2016-04-29 | 2017-05-01 | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060872A Division JP2023085437A (ja) | 2016-04-29 | 2023-04-04 | 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515926A JP2019515926A (ja) | 2019-06-13 |
| JP2019515926A5 true JP2019515926A5 (enExample) | 2020-06-18 |
| JP7262100B2 JP7262100B2 (ja) | 2023-04-21 |
Family
ID=60161161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018556339A Active JP7262100B2 (ja) | 2016-04-29 | 2017-05-01 | 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 |
| JP2023060872A Pending JP2023085437A (ja) | 2016-04-29 | 2023-04-04 | 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060872A Pending JP2023085437A (ja) | 2016-04-29 | 2023-04-04 | 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190290593A1 (enExample) |
| EP (2) | EP3448364B1 (enExample) |
| JP (2) | JP7262100B2 (enExample) |
| CN (2) | CN116077439A (enExample) |
| AU (3) | AU2017257189B2 (enExample) |
| CA (1) | CA3021645A1 (enExample) |
| DK (1) | DK3448364T3 (enExample) |
| ES (1) | ES2913073T3 (enExample) |
| PL (1) | PL3448364T3 (enExample) |
| PT (1) | PT3448364T (enExample) |
| WO (1) | WO2017190145A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3448364B1 (en) | 2016-04-29 | 2022-02-09 | Icahn School of Medicine at Mount Sinai | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
| AU2018370237B2 (en) * | 2017-11-20 | 2024-10-17 | Icahn School Of Medicine At Mount Sinai | Inhibiting trained immunity with a therapeutic nanobilogic composition |
| US20230001010A1 (en) * | 2019-07-19 | 2023-01-05 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disorders |
| BR112022009934A2 (pt) * | 2019-11-22 | 2022-08-09 | Univ New York State Res Found | Método para prevenir ou tratar diabetes tipo 1, e, composição compreendendo lipossomas |
| CN111494320A (zh) * | 2020-04-24 | 2020-08-07 | 上海交通大学医学院附属仁济医院 | 一种载糖皮质激素的纳米载体及其制备和应用 |
| CA3187283A1 (en) * | 2020-06-29 | 2022-01-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-protein s single-domain antibodies and polypeptides comprising thereof |
| WO2022198101A1 (en) * | 2021-03-19 | 2022-09-22 | Trained Therapeutix Discovery, Inc. | Compounds for regulating trained immunity, and their methods of use |
| CN114788835B (zh) * | 2022-04-07 | 2024-01-23 | 中山大学附属第三医院 | Foxp3阳性巨噬细胞在制备治疗急性脑梗死药物中的应用 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI66878C (fi) | 1978-02-24 | 1984-12-10 | Ciba Geigy Ag | Foerfarande foer framstaellning av nya antigenderivat |
| JPS5528933A (en) | 1978-08-21 | 1980-02-29 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide dimer |
| JPS5618996A (en) | 1979-06-21 | 1981-02-23 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide derivative |
| FI75578C (fi) | 1979-07-25 | 1988-07-11 | Ciba Geigy Ag | Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider. |
| JPS58172399A (ja) | 1982-04-05 | 1983-10-11 | Dai Ichi Seiyaku Co Ltd | ムラミルトリペプチド誘導体 |
| EP0102319B1 (de) | 1982-07-23 | 1987-08-19 | Ciba-Geigy Ag | Verwendung von Muramylpeptiden oder deren Analogen zur Prophylaxe und Therapie von Virusinfektionen |
| ZA853989B (en) | 1984-05-29 | 1986-01-29 | Ciba Geigy Ag | Acylated sugar derivatives,processes for their manufacture,and their use |
| JPS6157597A (ja) | 1984-08-29 | 1986-03-24 | Toshiyuki Hamaoka | ムラミルペプチド活性エステル誘導体 |
| EP0192609A3 (de) | 1985-02-20 | 1988-04-27 | Ciba-Geigy Ag | Acylierte Hexosederivate und Verfahren zu ihrer Herstellung |
| EP0192611A3 (de) | 1985-02-20 | 1988-05-11 | Ciba-Geigy Ag | Acylierte Hexosederivate und Verfahren zu ihrer Herstellung |
| US4640911A (en) | 1985-05-29 | 1987-02-03 | Ciba-Geigy Corporation | Acylated sugar derivatives, processes for their manufacture, and their use |
| US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| DE69230041T2 (de) | 1991-11-19 | 2000-01-05 | Peptech (Uk) Ltd., London | Muramylverbindungen zur behandlung von septischem schock |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5349060A (en) | 1993-01-07 | 1994-09-20 | American Home Products Corporation | Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| GB9320820D0 (en) | 1993-10-08 | 1993-12-01 | Biokine Tech Ltd | Compounds for medicinal use |
| CN1046944C (zh) | 1993-12-17 | 1999-12-01 | 山道士有限公司 | 雷怕霉素类衍生物 |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| GB9413935D0 (en) | 1994-07-11 | 1994-08-31 | Peptech Uk Ltd | Use of maramyl peptide compounds |
| GB9419011D0 (en) | 1994-09-21 | 1994-11-09 | Peptech Uk Ltd | Use of muramyl peptide compounds |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5985890A (en) | 1995-06-09 | 1999-11-16 | Novartis Ag | Rapamycin derivatives |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| GB9618673D0 (en) | 1996-09-06 | 1996-10-16 | Peptech Uk Ltd | The use of muramyl peptides |
| CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| US7592008B2 (en) | 2000-11-20 | 2009-09-22 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Membrane scaffold proteins |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| EP1605972A2 (en) | 2003-03-26 | 2005-12-21 | Cytos Biotechnology AG | Hiv-peptide-carrier-conjugates |
| KR20120105062A (ko) | 2003-12-19 | 2012-09-24 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 소프트 또는 임프린트 리소그래피를 이용하여 분리된 마이크로- 및 나노- 구조를 제작하는 방법 |
| CN1942476A (zh) | 2004-04-14 | 2007-04-04 | 惠氏公司 | 纳巴霉素42－酯衍生物的区位特异合成 |
| KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
| EP1768692B8 (en) | 2004-07-01 | 2015-06-17 | Yale University | Targeted and high density drug loaded polymeric materials |
| CA2587411A1 (en) | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| JP2009504192A (ja) | 2005-08-19 | 2009-02-05 | サイリーン ファーマシューティカルズ インコーポレーティッド | ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用 |
| WO2008124165A2 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| CN101096386A (zh) | 2007-06-05 | 2008-01-02 | 复旦大学 | Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| JP5824213B2 (ja) | 2007-10-05 | 2015-11-25 | センワ バイオサイエンシズ インコーポレイテッド | キノロン類似体およびそれに関連する方法 |
| EP2394657A1 (en) | 2007-10-12 | 2011-12-14 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
| EP2217221B1 (en) | 2007-10-17 | 2018-06-27 | Korea Advanced Institute of Science and Technology | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
| WO2009073984A1 (en) | 2007-12-12 | 2009-06-18 | University Health Network | High-density lipoprotein-like peptide-phospholipid scaffold ('hpps') nanoparticles |
| WO2009106999A2 (en) | 2008-02-28 | 2009-09-03 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Hollow nanoparticles and uses thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8268796B2 (en) | 2008-06-27 | 2012-09-18 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use thereof |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| WO2010048452A2 (en) | 2008-10-22 | 2010-04-29 | Kathryn Jill Chavez | Polycyclic compounds and methods related thereto |
| US20120015899A1 (en) | 2008-10-25 | 2012-01-19 | Plant Bioscience, Limited | Modified plant virus particles and uses therefor |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| WO2010147992A1 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Methods for increasing efficacy of lipid formulated sirna |
| WO2011044545A2 (en) | 2009-10-09 | 2011-04-14 | Sigalov Alexander B | Methods and compositions for targeted imaging |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012026712A2 (ko) | 2010-08-23 | 2012-03-01 | 주식회사 강스템홀딩스 | Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 |
| KR101253399B1 (ko) * | 2010-10-26 | 2013-04-11 | 영남대학교 산학협력단 | 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형 |
| US20140086839A1 (en) | 2011-03-17 | 2014-03-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| CN102178954B (zh) | 2011-04-25 | 2014-05-28 | 中国药科大学 | 具有血管壁靶向和逆向转运胆固醇功能的重组高密度脂蛋白载药系统及其应用 |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2013192310A1 (en) * | 2012-06-19 | 2013-12-27 | Massachusetts Institute Of Technology | Mass production and size control of nanoparticles through controlled microvortices |
| EP2703384A1 (en) | 2012-08-27 | 2014-03-05 | Ludwig-Maximilians-Universität München | Inhibitors of CD40-TRAF6 interaction |
| CN103589699B (zh) | 2013-11-05 | 2015-05-13 | 江南大学 | 一种可溶性淀粉底物特异性提高的环糊精糖基转移酶 |
| EP4461372A3 (en) | 2013-11-05 | 2025-01-22 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| ES2754207T3 (es) | 2013-11-28 | 2020-04-16 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Inhibidores de la ARN polimerasa I y usos de los mismos |
| RS66380B1 (sr) | 2014-04-23 | 2025-02-28 | Modernatx Inc | Vakcine nukleinske kiseline |
| WO2016019333A1 (en) | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
| WO2016138286A1 (en) | 2015-02-26 | 2016-09-01 | Stc.Unm | Irgm and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy |
| US11642419B2 (en) | 2015-03-25 | 2023-05-09 | The Regents Of The University Of Michigan | Compositions and methods for treating cardiovascular related disorders |
| CA2979712C (en) | 2015-03-25 | 2024-01-23 | The Regents Of The University Of Michigan | Nanoparticle compositions for delivery of biomacromolecules |
| WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
| CA2983033A1 (en) | 2015-04-20 | 2016-10-27 | Memorial Sloan Kettering Cancer Center | Imaging of tumor-associated macrophages |
| WO2016172615A1 (en) | 2015-04-24 | 2016-10-27 | University Of Delaware | Synthetic n-acetyl-muramic acid derivatives and uses thereof |
| CN106714836A (zh) | 2015-06-05 | 2017-05-24 | H·李·莫菲特癌症中心研究有限公司 | Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗 |
| JP2018521068A (ja) | 2015-07-15 | 2018-08-02 | セレーター ファーマシューティカルズ インコーポレイテッド | 改善されたナノ粒子送達系 |
| WO2017024312A1 (en) | 2015-08-06 | 2017-02-09 | Autotelic Llc | Phospholipid-cholesteryl ester nanoformulations and related methods |
| EP3389635A4 (en) * | 2015-12-18 | 2019-08-07 | Northwestern University | STAIN OXIDE-RELATED NANOPARTICLES OF SIMILARITY WITH HIGH-DENSITY LIPOPROTEINS |
| US20190008918A1 (en) | 2016-03-08 | 2019-01-10 | Bioxcel Corporation | Immunomodulation therapies for cancer |
| EP3448364B1 (en) * | 2016-04-29 | 2022-02-09 | Icahn School of Medicine at Mount Sinai | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
| JP7160688B2 (ja) | 2016-05-24 | 2022-10-25 | ジェネンテック， インコーポレイテッド | Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用 |
| WO2018071549A1 (en) | 2016-10-11 | 2018-04-19 | New York University | Nanoparticles and uses thereof |
| CN106831614B (zh) | 2017-01-09 | 2020-07-28 | 清华大学 | 取代的苯并二氮杂环类化合物及其制备方法和用途 |
| IL302880A (en) | 2017-04-04 | 2023-07-01 | Avidea Tech Inc | Peptide-based ingredients, production methods, and their uses for inducing an immune response |
| AU2018370237B2 (en) | 2017-11-20 | 2024-10-17 | Icahn School Of Medicine At Mount Sinai | Inhibiting trained immunity with a therapeutic nanobilogic composition |
| EP3713548A4 (en) | 2017-11-21 | 2021-06-23 | Icahn School of Medicine at Mount Sinai | Promoting trained immunity with therapeutic nanobiologic compositions |
| KR102198900B1 (ko) | 2019-05-10 | 2021-01-07 | 서강대학교 산학협력단 | 질병 치료용 나노입자 복합체 및 이의 제조방법 |
| WO2022198101A1 (en) | 2021-03-19 | 2022-09-22 | Trained Therapeutix Discovery, Inc. | Compounds for regulating trained immunity, and their methods of use |
| EP4499052A2 (en) | 2022-03-31 | 2025-02-05 | Icahn School of Medicine at Mount Sinai | Sphingolipid-loaded nanobiologics for immune regulation |
-
2017
- 2017-05-01 EP EP17790646.8A patent/EP3448364B1/en active Active
- 2017-05-01 PL PL17790646.8T patent/PL3448364T3/pl unknown
- 2017-05-01 CA CA3021645A patent/CA3021645A1/en active Pending
- 2017-05-01 AU AU2017257189A patent/AU2017257189B2/en active Active
- 2017-05-01 CN CN202310107087.1A patent/CN116077439A/zh active Pending
- 2017-05-01 ES ES17790646T patent/ES2913073T3/es active Active
- 2017-05-01 JP JP2018556339A patent/JP7262100B2/ja active Active
- 2017-05-01 US US16/097,013 patent/US20190290593A1/en not_active Abandoned
- 2017-05-01 WO PCT/US2017/030444 patent/WO2017190145A1/en not_active Ceased
- 2017-05-01 EP EP22155443.9A patent/EP4014967A1/en active Pending
- 2017-05-01 PT PT177906468T patent/PT3448364T/pt unknown
- 2017-05-01 CN CN201780041257.3A patent/CN109640959B/zh active Active
- 2017-05-01 DK DK17790646.8T patent/DK3448364T3/da active
-
2022
- 2022-06-30 AU AU2022204675A patent/AU2022204675B2/en active Active
-
2023
- 2023-03-14 US US18/121,527 patent/US12377054B2/en active Active
- 2023-04-04 JP JP2023060872A patent/JP2023085437A/ja active Pending
-
2025
- 2025-08-14 AU AU2025217324A patent/AU2025217324A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515926A5 (enExample) | ||
| Hu et al. | Recent developments of coumarin-containing derivatives and their anti-tubercular activity | |
| Xu et al. | Design, synthesis and in vitro anti-mycobacterial evaluation of gatifloxacin-1H-1, 2, 3-triazole-isatin hybrids | |
| Chatterji et al. | 1, 4-Azaindole, a potential drug candidate for treatment of tuberculosis | |
| Kim et al. | A novel 3, 4-dihydropyrimidin-2 (1H)-one: HIV-1 replication inhibitors with improved metabolic stability | |
| Jia et al. | Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors | |
| Peng et al. | Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1, 3-benzothiazin-4-one derivatives | |
| Li et al. | Design, synthesis, and evaluation of tetrahydropyrrolo [1, 2-c] pyrimidines as capsid assembly inhibitors for HBV treatment | |
| CN103842350B (zh) | 作为dhodh抑制剂的五元二氢杂环酮类衍生物及应用 | |
| CN103006645A (zh) | 2-氨基苯并噻唑衍生物作为dhodh抑制剂的应用 | |
| AU2015293506B2 (en) | Isoindolinone derivatives useful as antiviral agents | |
| Macchi et al. | 1H-Benzo [d] imidazoles and 3, 4-dihydroquinazolin-4-ones: Design, synthesis and antitubercular activity | |
| HUE032004T2 (en) | Use of a pyrazole derivative for the treatment of acute severe conditions of chronic obstructive airways disease | |
| Avalos-Alanís et al. | Synthesis, antimycobacterial and cytotoxic activity of α, β-unsaturated amides and 2, 4-disubstituted oxazoline derivatives | |
| JP2007522135A5 (enExample) | ||
| US10913766B2 (en) | Liver specific delivery-based entecavir prodrug, nucleoside cyclic phosphate compound, and application thereof | |
| Pieroni et al. | Discovery of antitubercular 2, 4-diphenyl-1H-imidazoles from chemical library repositioning and rational design | |
| JP6980779B2 (ja) | 肝臓送達に基づく抗ウイルス性プロドラッグであるヌクレオシド環状リン酸エステル化合物およびその使用 | |
| JP7209723B2 (ja) | 肝臓送達に基づくゲムシタビンプロドラッグであるヌクレオシドの環状リン酸エステル化合物および応用 | |
| Villemagne et al. | Recent advances in Fragment-based strategies against tuberculosis | |
| JPWO2021262484A5 (enExample) | ||
| Da Costa et al. | Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: a combined computational and experimental study | |
| Lv et al. | Identification of (6S)-cyclopropyl-6, 7-dihydropyrazolo [1, 5-a] pyrazine-5 (4H)-carboxamines as new HBV capsid assembly modulators | |
| TW201341377A (zh) | 作為ｐａｒ－受體拮抗劑之雙環喜巴辛（ｈｉｍｂａｃｉｎｅ）衍生物之製備及用途 | |
| Ren et al. | Design, synthesis, and bioevaluation of a novel class of (E)-4-oxo-crotonamide derivatives as potent antituberculosis agents |